— Trial discovers comparable issue and reoccurrence rates with hypofractionated versus basic RT
by Mike Bassett, Personnel Writer, MedPage Today
October 1, 2024
Hypofractionated post-mastectomy radiation treatment (RT) with breast restoration showed noninferior to basic RT when it pertained to restoration issues, state-of-the-art toxicity, and regional control, according to arise from a stage III trial.
In the RT CHARM research study, the restoration problem rate at 2 years was statistically no various, at 14% with the hypofractionated routine versus 12% with standard RT (P=0.0004 for noninferiority), reported Matthew Poppe, MD, of the University of Utah Huntsman Cancer Institute in Salt Lake City.
In addition, he detailed at the American Society for Radiation Oncology (ASTRO) yearly conference in Washington, D.C., secondary endpoints revealed no distinctions in between groups for grade ≥ 3 intense or late problems of RT:
- Severe: 5% vs 7.7%, respectively
- Late: 6.1% vs 5.5%
When it comes to the rate of regional and locoregional reoccurrence, once again there was no distinction, Poppe observed, “with a total low rate of reoccurrence in this population that is reasonably greater threat since of their nodal positivity.” At 3 years, the short-course radiation arm had a reoccurrence rate of 1.5% compared to 1.9% in the standard fractionation arm.
ASTRO-discussant Kathleen Horst, MD, of Stanford University in California, stated that with the arise from 3 randomized trials– RT CHARM together with FABREC and a trial from China– “we can now state that moderate, hypofractionated post-mastectomy radiation is safe compared to basic fractionation, with comparable local regional reoccurrences, toxicity profiles, and restoration problems.”
Together, the trials registered over 2,000 clients, “with 50-60% being under 50 or premenopausal, and the bulk getting chemotherapy and local nodal irradiation,” she stated. “We now have information for implant-based restoration along with autologous restoration.”
From 2018 to 2021, the RT CHARM research study registered 898 clients (825 evaluable) with unilateral